Cargando…

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrisette, Taylor, Alosaimy, Sara, Philley, Julie V, Wadle, Carly, Howard, Catessa, Webb, Andrew J, Veve, Michael P, Barger, Melissa L, Bouchard, Jeannette, Gore, Tristan W, Lagnf, Abdalhamid M, Ansari, Iman, Mejia-Chew, Carlos, Cohen, Keira A, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890947/ https://www.ncbi.nlm.nih.gov/pubmed/33628856 http://dx.doi.org/10.1093/ofid/ofab002

Ejemplares similares

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2021)

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022)

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
por: El Ghali, Amer, et al.
Publicado: (2023)

Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
por: Holger, Dana J., et al.
Publicado: (2022)

Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
por: Bich Hanh, Bui Thi, et al.
Publicado: (2021)

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis
por: Alosaimy, Sara, et al.
Publicado: (2020)

Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19
por: Rebold, Nicholas, et al.
Publicado: (2022)

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
por: Alosaimy, Sara, et al.
Publicado: (2022)

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
por: Pearson, Jeffrey C, et al.
Publicado: (2020)

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus
por: Bax, Hannelore I, et al.
Publicado: (2019)

Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature
por: Siddiqa, Ayesha, et al.
Publicado: (2023)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
por: Li, Anqi, et al.
Publicado: (2023)

Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
por: Mingora, Christina M, et al.
Publicado: (2023)

Correction to: Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
Publicado: (2023)

Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages
por: Jahanbakhsh, S, et al.
Publicado: (2023)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
por: Rebold, Nicholas, et al.
Publicado: (2023)

COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options
por: Rebold, Nicholas, et al.
Publicado: (2021)

Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease
por: Rimal, Binayak, et al.
Publicado: (2023)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022)

Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use
por: Rizzo, Ashley R., et al.
Publicado: (2022)

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy
por: Morrisette, Taylor, et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study
por: Alosaimy, Sara, et al.
Publicado: (2021)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection
por: Alosaimy, Sara, et al.
Publicado: (2020)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1061. Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center
por: Claeys, Kimberly C., et al.
Publicado: (2015)

Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis
por: Claeys, Kimberly C., et al.
Publicado: (2017)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gaptfe3jmjq67iofmj0pht048e